Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy. HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the. treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases. HT-003 to treat inflammatory bowel diseases, as well as acne and psor
